Détail de l'auteur
Documents disponibles écrits par cet auteur
trié(s) par (Pertinence décroissant(e), Date de parution décroissant(e), Date de parution décroissant(e), Système de projection du document croissant(e)) | Mettre toutes les notices dans le panier | Faire une suggestion | Ajouter un critère de recherche
Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys.
Losen M, Labrijn AF, van Kranen-Mastenbroek VH, et al.
Scientific Reports, 2017, 7, 1, sp
Silencing of Dok-7 in Adult Rat Muscle Increases Susceptibility to Passive Transfer Myasthenia Gravis.
Gomez AM, Stevens JA, Mane-Damas M, et al.
The American journal of pathology, 2016, 186, 10, 2559-68
Titin antibodies in "seronegative" myasthenia gravis - A new role for an old antigen.
Stergiou C, Lazaridis K, Zouvelou V, et al.
Journal of neuroimmunology, 2016, 292, p. 108-115
Congenital Myasthenic Syndrome Type 19 Is Caused by Mutations in COL13A1, Encoding the Atypical Non-fibrillar Collagen Type XIII alpha-1 Chain.
Logan CV, Cossins J, Rodríguez Cruz PM, et al.
2015, p. 878-885
MuSK autoantibodies in myasthenia gravis detected by cell based assay - A multinational study.
Tsonis AI, Zisimopoulou P, Lazaridis K, et al.
Journal of neuroimmunology, 2015, 284, p. 10-7
Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor.
Vrolix K, Fraussen J, Losen M, et al.
Journal of autoimmunity, 2014, 52, p. 101-12
A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis
Zisimopoulou P, Evangelakou P, Tzartos J, et al.
Journal of autoimmunity, 2014, 52, p. 139-145
Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4
Verschuuren JJGM, Huijbers MG, Plomp JJ, et al.
Autoimmunity reviews, 2013, 12, 9, p. 918-923
Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis
Cufi P, Dragin N, Weiss JM, et al.
Annals of neurology, 2013, 73, 2, p. 281-293
Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice
Klooster R, Plomp JJ, Huijbers MG, et al.
Brain, 2012, 135, 4, p. 1081-1101
Treatment of myasthenia gravis by preventing acetylcholine receptor modulation
Losen M, Martinez-Martinez P, Phernambucq M, et al.
Annals of the New York Academy of Sciences, 2008, 1132, p. 174-179
Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis
Losen M, Stassen MHW, Martinez-Martinez P, et al.
Brain, 2005, 128, 10, p. 2327-2337
Rapsyn gene therapy of experimental autoimmune myasthenia gravis (abstract : congrès international de Myologie, 2005)
Martinez-Martinez P, Losen M, Van de Waarenburg M, et al.
Congrès : Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France)
2005, p. 266
Recombinant antibodies for MG therapy (abstract : congrès international de Myologie, 2005)
Losen M, Martinez-Martinez P, Machiels BM
Congrès : Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France)
2005, p. 258
The auto-antigen repertoire in myasthenia gravis
Vrolix K, Fraussen J, Molenaar PC, et al.
Autoimmunity, 08-09/2010, 43, 4-5, p. 380-400
Antibody effector mechanisms in myasthenia gravis-Pathogenesis at the neuromuscular junction
Gomez AM, Van den Broeck J, Vrolix K, et al.
Autoimmunity, 08-09/2010, 43, 5-6, p. 353-370
